Cargando…
Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
BACKGROUND: Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later per...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314741/ https://www.ncbi.nlm.nih.gov/pubmed/37397011 http://dx.doi.org/10.7717/peerj.15072 |
_version_ | 1785067372794609664 |
---|---|
author | Rahmadani, Imanda Dyah Irawati, Sylvi Wibowo, Yosi Irawati Setiadi, Adji Prayitno |
author_facet | Rahmadani, Imanda Dyah Irawati, Sylvi Wibowo, Yosi Irawati Setiadi, Adji Prayitno |
author_sort | Rahmadani, Imanda Dyah |
collection | PubMed |
description | BACKGROUND: Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later period of the disease are still limited. This study aims to identify the pattern of pDDIs in hospitalized COVID-19 patients with comorbidities and their associated factors, especially in the second wave of the disease in Indonesia. METHODS: This study was a longitudinal-retrospective study observing hospitalized COVID-19 patients with comorbidities using medical record data in June–August 2021 at a public hospital in a region in Indonesia. pDDIs were identified using the Lexicomp(®) database. Data were descriptively analyzed. Factors associated with important pDDIs were analyzed in multivariate logistic regression model. RESULTS: A total of 258 patients with a mean age of 56.99 ± 11.94 years met the inclusion criteria. Diabetes mellitus was the most common comorbidity experienced by 58.14% of the patients. More than 70% of the patients had one comorbidity and the average number of administered drugs was 9.55 ± 2.71 items per patient. Type D pDDIs, which required modification of therapeutic regimens, amounted to 21.55% of the total interactions. Only the number of drugs was significantly and independently associated with type D pDDIs (adjusted odds ratio 1.47 [1.23–1.75], p < 0.01). CONCLUSION: The drugs involved in the pDDIs of hospitalized COVID-19 patients with comorbidities may differ depending on the disease periods, hospital settings, or countries. This study was small, single center, and of short duration. However, it may give a glimpse of important pDDIs during the delta variant of COVID-19 in a similar limited-resource setting. Further studies are needed to confirm the clinical significance of these pDDIs. |
format | Online Article Text |
id | pubmed-10314741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103147412023-07-02 Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities Rahmadani, Imanda Dyah Irawati, Sylvi Wibowo, Yosi Irawati Setiadi, Adji Prayitno PeerJ Drugs and Devices BACKGROUND: Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later period of the disease are still limited. This study aims to identify the pattern of pDDIs in hospitalized COVID-19 patients with comorbidities and their associated factors, especially in the second wave of the disease in Indonesia. METHODS: This study was a longitudinal-retrospective study observing hospitalized COVID-19 patients with comorbidities using medical record data in June–August 2021 at a public hospital in a region in Indonesia. pDDIs were identified using the Lexicomp(®) database. Data were descriptively analyzed. Factors associated with important pDDIs were analyzed in multivariate logistic regression model. RESULTS: A total of 258 patients with a mean age of 56.99 ± 11.94 years met the inclusion criteria. Diabetes mellitus was the most common comorbidity experienced by 58.14% of the patients. More than 70% of the patients had one comorbidity and the average number of administered drugs was 9.55 ± 2.71 items per patient. Type D pDDIs, which required modification of therapeutic regimens, amounted to 21.55% of the total interactions. Only the number of drugs was significantly and independently associated with type D pDDIs (adjusted odds ratio 1.47 [1.23–1.75], p < 0.01). CONCLUSION: The drugs involved in the pDDIs of hospitalized COVID-19 patients with comorbidities may differ depending on the disease periods, hospital settings, or countries. This study was small, single center, and of short duration. However, it may give a glimpse of important pDDIs during the delta variant of COVID-19 in a similar limited-resource setting. Further studies are needed to confirm the clinical significance of these pDDIs. PeerJ Inc. 2023-06-28 /pmc/articles/PMC10314741/ /pubmed/37397011 http://dx.doi.org/10.7717/peerj.15072 Text en ©2023 Rahmadani et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Drugs and Devices Rahmadani, Imanda Dyah Irawati, Sylvi Wibowo, Yosi Irawati Setiadi, Adji Prayitno Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities |
title | Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities |
title_full | Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities |
title_fullStr | Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities |
title_full_unstemmed | Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities |
title_short | Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities |
title_sort | potential drug-drug interactions and their associated factors in hospitalized covid-19 patients with comorbidities |
topic | Drugs and Devices |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314741/ https://www.ncbi.nlm.nih.gov/pubmed/37397011 http://dx.doi.org/10.7717/peerj.15072 |
work_keys_str_mv | AT rahmadaniimandadyah potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities AT irawatisylvi potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities AT wibowoyosiirawati potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities AT setiadiadjiprayitno potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities |